Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21029776 | 0.91 | — | — | |
| SCHEMBL26252885 | 0.83 | — | — | |
| SCHEMBL20756564 | 0.83 | NOD1 (0.36) | NOD1KMT2APOLB | |
| SCHEMBL20643464 | 0.81 | NOD1 (0.36) | NOD1KMT2APOLB | |
| SCHEMBL16248525 | 0.81 | NOD1 (0.36) | NOD1KMT2APOLB | |
| SCHEMBL16248526 | 0.81 | NOD1 (0.36) | NOD1KMT2APOLB | |
| SCHEMBL21029641 | 0.81 | — | — | |
| SCHEMBL25772845 | 0.80 | NOD1 (0.40) | NOD1KMT2APOLB | |
| SCHEMBL18513225 | 0.80 | NOD1 (0.38) | NOD1KMT2APOLB | |
| SCHEMBL25448139 | 0.78 | CTSC (0.34) | NOD1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683499-B2 | Compositions and methods for modulating TTR expression | IONIS PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20180044676-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | IONIS PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044676-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | NOD1 1089/4885KMT2A 3611/4885POLB 4492/4885 |
| US-10683499-B2 | Compositions and methods for modulating TTR expression | TTR, GALNT1, GALNT3 | NOD1 1089/4885KMT2A 3611/4885POLB 4492/4885 |
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | ACOT7, COASY, LCAT | NOD1 4057/4885KMT2A 849/4885POLB 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.